Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

ALG-000184 Has Favorable Antiviral Effect & Safety in Untreated Asian/Non-Asian HBeAg-Negative CHB Subjects

Wednesday, March 27, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses the positive results of ALG-000184, an antiviral treatment for untreated HBeAg-negative chronic hepatitis B (CHB) subjects. The study highlights its favorable antiviral effects and safety profile, demonstrating efficacy across both Asian and Non-Asian populations. These findings may contribute to improved treatment options for chronic HBV infection.
Price reaction · baseline $25.0025 (2024-03-27T17:55:00.000Z) · hit during market hours · clean, no other ALGS news in the window
day 0 close · peak
-2.1%

Market Sentiment Analysis

POSITIVE FACTORS

  • ALG-000184 shows favorable antiviral effects.
  • Safety profile is promising in clinical trials.
  • Study includes diverse populations (Asian and Non-Asian).

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

• About Overview Management Board of Directors
• Science Pipeline Posters & Presentations
• Patients Chronic HBV Infection MASH Clinical Trials Expanded Access Policy
• News & Media Press Releases Presentations & Events
• Investors Overview Stock Stock Quote & Chart Analyst Coverage News & Events News Releases Investor Calendar Financials SEC Filings Quarterly Results Governance Governance Highlights Committee Composition Resources Investor FAQs Email Alerts Contact IR
• Careers
• Overview
• Management
• Board of Directors
• Pipeline
• Posters & Presentations
• Chronic HBV Infection
• MASH
• Clinical Trials
• Expanded Access Policy
• Press Releases
• Presentations & Events
• Overview
• Stock Stock Quote & Chart Analyst Coverage
• News & Events News Releases Investor Calendar
• Financials SEC Filings Quarterly Results
• Governance Governance Highlights Committee Composition
• Resources Investor FAQs Email Alerts Contact IR
• Stock Quote & Chart
• Analyst Coverage
• News Releases
• Investor Calendar
• SEC Filings
• Quarterly Results
• Governance Highlights
• Committee Composition
• Investor FAQs
• Email Alerts
• Contact IR

Frequently Asked Questions

What is ALG-000184?

ALG-000184 is an antiviral treatment for chronic hepatitis B infection.

What populations were included in the study?

The study included both Asian and Non-Asian HBeAg-negative subjects.

What were the results of the ALG-000184 study?

The study showed favorable antiviral effects and a promising safety profile.

Is ALG-000184 safe for patients?

Yes, the safety profile of ALG-000184 is considered promising based on the study.

ShareAdd on Google
Tags: ALGS Viatris Investor Conferences Healthcare ALG-000184 chronic hepatitis B antiviral treatment HBeAg-negative clinical trials
Last updated: Mar 27, 2024

Biotech snapshot

Cash runway
$30M liquidity · $8M/mo burn
~3 mo
High dilution risk
Lead asset
ALG-055009Phase 2
NASH →

Catalyst track record

+153%
best trade around ALGS's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALGS.

See every catalyst's timing & PoA →